Molecular alterations in meningioma: prognostic and therapeutic perspectives

Birzu, Cristina; Peyre, Matthieu; Sahm, Felix

doi:10.1097/cco.0000000000000687

Cited by 58 publications

(43 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meningiomas are the most common primary intracranial tumors, 80% of which are benign, with 1–5% localized in the medial anterior skull base. The predominant histology of those tumors is meningothelial and are linked to mutations in SMO gene, locus 7p32.1 [ 15 ]. Due to the location of the tumor, this type of benign meningioma is suspected, however, genetic tests were not performed.…”

Section: Discussionmentioning

confidence: 99%

Atypical Charles Bonnet syndrome secondary to frontal meningioma: a case report

et al. 2021

View full text Add to dashboard Cite

Background Charles Bonnet Syndrome (CBS) is a rare clinical entity that is classically composed of visual hallucinations in the context of an altered optic pathway with preservation of reality judgment. This case aims to present the association of visual hallucinations with complex alterations of the nervous structures adjacent to the visual pathway and an atypical clinical presentation, thus explaining the possible mechanisms involved in the generation of these symptoms. Case presentation A 43-year-old man presents seeking care due to visual hallucinations with partial preservation of reality judgment and symptoms compatible with a major depressive disorder, including irritability and diminished hygiene habits. He has a history of complete gradual loss of vision and hyposmia. Due to poor treatment response during hospitalization, an MRI was obtained, which showed a frontal tumor lesion with meningioma characteristics adjacent to the olfactory groove and compression of the optic chiasm. He underwent surgical resection of the lesion, which remitted the psychotic symptoms, but preserving the visual limitation and depressive symptoms. Conclusions The presence of visual hallucinations, without other psychotic features as delusions, is a focus of attention for basic structural pathologies in the central nervous system. Affection at any level of the visual pathway can cause CBS. When finding atypical symptoms, a more in-depth evaluation should be made to allow optimization of the diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Atypical Charles Bonnet syndrome secondary to frontal meningioma: a case report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Numerous studies have identified multiple signaling pathways involved in the therapeutic resistance of high-grade meningiomas and have suggested many important molecular targets for the development of new drugs for the treatment of high-grade meningiomas that are resistant to radio-and chemotherapy. In particular, growth factors, such as PDGF, epidermal growth factor (EGF) and their receptors, and cytokines, such as TGF-β, serve as major factors in high-grade meningiomas leading to therapeutic resistance (Birzu et al, 2020;Shao et al, 2020).…”

Section: High-grade Meningiomasmentioning

confidence: 99%

The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors

Gareev

Beylerli

Liang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Brain tumors in children and adults are challenging tumors to treat. Malignant primary brain tumors (MPBTs) such as glioblastoma have very poor outcomes, emphasizing the need to better understand their pathogenesis. Developing novel strategies to slow down or even stop the growth of brain tumors remains one of the major clinical challenges. Modern treatment strategies for MPBTs are based on open surgery, chemotherapy, and radiation therapy. However, none of these treatments, alone or in combination, are considered effective in controlling tumor progression. MicroRNAs (miRNAs) are 18–22 nucleotide long endogenous non-coding RNAs that regulate gene expression at the post-transcriptional level by interacting with 3′-untranslated regions (3′-UTR) of mRNA-targets. It has been proven that miRNAs play a significant role in various biological processes, including the cell cycle, apoptosis, proliferation, differentiation, etc. Over the last decade, there has been an emergence of a large number of studies devoted to the role of miRNAs in the oncogenesis of brain tumors and the development of resistance to radio- and chemotherapy. Wherein, among the variety of molecules secreted by tumor cells into the external environment, extracellular vesicles (EVs) (exosomes and microvesicles) play a special role. Various elements were found in the EVs, including miRNAs, which can be transported as part of these EVs both between neighboring cells and between remotely located cells of different tissues using biological fluids. Some of these miRNAs in EVs can contribute to the development of resistance to radio- and chemotherapy in MPBTs, including multidrug resistance (MDR). This comprehensive review examines the role of miRNAs in the resistance of MPBTs (e.g., high-grade meningiomas, medulloblastoma (MB), pituitary adenomas (PAs) with aggressive behavior, and glioblastoma) to chemoradiotherapy and pharmacological treatment. It is believed that miRNAs are future therapeutic targets in MPBTs and such the role of miRNAs needs to be critically evaluated to focus on solving the problems of resistance to therapy this kind of human tumors.

show abstract

“…New genomic analysis techniques such as whole genomic sequencing (WGS), transcriptome analysis, whole exome sequencing (WES), DNA methylation assay, and chromatin immunoprecipitation sequencing allowed the characterization of the mutational landscape of meningiomas, with consequent identification of possible druggable targets [19].…”

Section: Molecular Alterationsmentioning

confidence: 99%

Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets

et al. 2021

View full text Add to dashboard Cite

Meningiomas are the most common primary CNS tumors. They are usually benign but can present aggressive behavior in about 20% of cases. The genetic landscape of meningioma is characterized by the presence (in about 60% of cases) or absence of NF2 mutation. Low-grade meningiomas can also present other genetic alterations, particularly affecting SMO, TRAF7, KLF4 AKT1 and PI3KCA. In higher grade meningiomas, mutations of TERT promoter and deletion of CDKN2A/B seem to have a prognostic value. Furthermore, other genetic alterations have been identified, such as BAP1, DMD and PBRM1. Different subgroups of DNA methylation appear to be correlated with prognosis. In this review, we explored the genetic landscape of meningiomas and the possible therapeutic implications.

show abstract

Molecular alterations in meningioma: prognostic and therapeutic perspectives

Cited by 58 publications

References 79 publications

Atypical Charles Bonnet syndrome secondary to frontal meningioma: a case report

Atypical Charles Bonnet syndrome secondary to frontal meningioma: a case report

The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors

Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets

Contact Info

Product

Resources

About